Regeneron looks to expand label of Eylea HD early next year
The high-dose version of Regeneron’s eye treatment Eylea hit its primary endpoint in a late-stage study for macular edema following retinal vein occlusion, a common …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
